» Articles » PMID: 9893112

Renal Disease and Hypertension in Non-insulin-dependent Diabetes Mellitus

Overview
Journal Kidney Int
Publisher Elsevier
Specialty Nephrology
Date 1999 Jan 20
PMID 9893112
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Recent epidemiologic data demonstrate a dramatic increase in the incidence of end-stage renal disease (ESRD) in patients with non-insulin-dependent diabetes mellitus (NIDDM), thus dispelling the mistaken belief that renal prognosis is benign in NIDDM. Currently, the leading cause of ESRD in the United States, Japan, and in most industrialized Europe is NIDDM, accounting for nearly 90% of all cases of diabetes. In addition to profound economic costs, patients with NIDDM and diabetic nephropathy have a dramatically increased morbidity and premature mortality. NIDDM-related nephropathy varies widely among racial and ethnic groups, genders and lifestyles; and gender may interact with race to affect the disease progression. While the course of insulin-dependent diabetes mellitus (IDDM) progresses through well-defined stages, the natural history of NIDDM is less well characterized. NIDDM patients with coronary heart disease have a higher urinary albumin excretion rate at the time of diagnosis and follow-up. This greater risk may also be associated with hypertension and hyperlipidemia, and genes involved in blood pressure are obvious candidate genes for diabetic nephropathy. Hyperglycemia appears to be an important factor in the development of proteinuria in NIDDM, but its role and the influence of diet are not yet clear. Tobacco smoking can also be deleterious to the diabetic patient, and is also associated with disease progression. Maintaining euglycemia, stopping smoking and controlling blood pressure may prevent or slow the progression of NIDDM-related nephropathy and reduce extrarenal injury. Treatment recommendations include early screening for hyperlipidemia, appropriate exercise and a healthy diet. Cornerstones of management should also include: (1) educating the medical community and more widely disseminating data supporting the value of early treatment of microalbuminuria; (2) developing a comprehensive, multidisciplinary team approach that involves physicians, nurses, diabetes educators and behavioral therapists; and (3) intensifying research in this field.

Citing Articles

The Ethyl Acetate Extract of L. Alleviates Diabetic Nephropathy in a Murine Model of Diabetes.

Lin C, Shih C Int J Mol Sci. 2024; 25(12).

PMID: 38928391 PMC: 11204328. DOI: 10.3390/ijms25126686.


The impact of GLP-1 receptor agonist liraglutide on blood pressure profile, hydration, natriuresis in diabetic patients with severely impaired kidney function.

Wajdlich M, Nowicki M Sci Rep. 2024; 14(1):5002.

PMID: 38424466 PMC: 10904847. DOI: 10.1038/s41598-024-55724-z.


Non-Diabetic Kidney Disease in Type 2 Diabetes Mellitus: A Changing Spectrum with Therapeutic Ascendancy.

Prasad N, Veeranki V, Bhadauria D, Kushwaha R, Meyyappan J, Kaul A J Clin Med. 2023; 12(4).

PMID: 36836240 PMC: 9964578. DOI: 10.3390/jcm12041705.


Changes in Clinical Manifestations Due to AFLD Retyping Based on the New MAFLD Criteria: An Observational Study Based on the National Inpatient Sample Database.

Feng X, Xuan R, Dong Y, Wu X, Cheng Y, Yuan Z Diagnostics (Basel). 2023; 13(3).

PMID: 36766593 PMC: 9914804. DOI: 10.3390/diagnostics13030488.


The role of exercise and hypoxia on glucose transport and regulation.

Soo J, Raman A, Lawler N, Goods P, Deldicque L, Girard O Eur J Appl Physiol. 2023; 123(6):1147-1165.

PMID: 36690907 PMC: 10191996. DOI: 10.1007/s00421-023-05135-1.